Category Archives: Patent

Hepatitis C: In Argentina INPI rejected a key patent on Sofosbuvir

Argentina has made an important step forward to protect  local production of generics of an essential medicine to treat Hepatitis C. This brings significant advantages for Public Programs which procure the medicines. Buenos Aires, December 4, 2017. In Argentina, the … Continue reading

Posted in Hepatitis C, Patent, Sofosbuvir, Uncategorized | Leave a comment

Doctors Without Borders contests Pfizer’s patent on pneumonia vaccine

Pfizer has come under fire for holding exclusive patent rights that bars competition on its pneumonia vaccine worldwide, which is being challenged in patent litigations in several countries, an aid group said Monday. Doctors Without Borders will challenge Pfizer in … Continue reading

Posted in Patent, Patent examination system, Patent Opposition, Uncategorized, Vaccines | Leave a comment

Time for costly medicine monopolies to go from TPP trade talks

Source: |November 9, 2017 Negotiators from 11 countries have been racing to resurrect the near-dead Trans-Pacific Partnership Agreement before the Asia-Pacific Economic Cooperation (APEC) summit this weekend. The latest plan to get the controversial trade deal up and running … Continue reading

Posted in Biologics/Biosimilars, Data Exclusivity, Patent, TPP, Uncategorized | Leave a comment

Gilead’s Patents on Hepatitis C Drug Challenged by Consumer Group

Source: Bloomberg Gilead Sciences Inc.’s U.S. patents on the blockbuster $84,000 hepatitis C treatment Sovaldi were challenged by a consumer group that’s battled the drugmaker around the world over the pricing.  The Initiative for Medicines, Access & Knowledge, a nonprofit focused on … Continue reading

Posted in Cancer, Evergreening, Hepatitis C, Patent, Uncategorized | Leave a comment

Greek health minister takes issue with Roche’s withdrawal of cancer medicine due to mandatory, retroactive discount

Source: EndPoints News Drug prices are not just a US problem. Greece’s minister of health on Tuesday expressed dismay over Roche’s decision to withdraw a cancer medicine because of a new mandatory discount imposed by the country. Greek health minister … Continue reading

Posted in Cancer, Compulsory Licensing, Patent, TRIPS, Uncategorized | 1 Comment

India to oppose anti-generics proposals at RCEP meet

Source: LiveMint India stands firm in opposing proposals that could hinder global access to affordable generic drugs and life-saving vaccines South Korea and Japan have been pushing for proposals to extend drug and vaccine patent terms, a move that is … Continue reading

Posted in Data Exclusivity, Generics, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized, WTO | Leave a comment

Global access to affordable medicines should not be restricted

MSF has witnessed the negative impact of monopoly pricing on life-saving medicines and vaccines in its medical projects all over the world. Courtesy- As 16 countries negotiating the Regional Comprehensive Economic Partnership (RCEP) agreement meet this week in Incheon, … Continue reading

Posted in Data Exclusivity, Generics, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS&IP rights, Uncategorized, WTO | Leave a comment